Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study

• Main Authors: Shelly Levi (Author), Daniel Landau (Author), Miriam Davidovits (Author), Mika Shapira Rootman (Author), Avivit Brener (Author), Shoshana Gal (Author), Yael Borovitz (Author), Ori Goldberg (Author), Rachel Bello (Author), Roxana Cleper (Author), Yael Lebenthal (Author), Yael Levy-Shraga (Author), Dov Tiosano (Author), Adi Chezana (Author), Ravit Regev (Author), Leonid Zeitlin (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundX-linked hypophosphatemic rickets (XLH) is associated with uninhibited FGF23 activity, which leads to phosphaturia, hypophosphatemia and depressed active vitamin D (1,25OH2D) levels. Conventional treatment with phosphate supplements and vitamin D analogs may lead to hypercalciuria (HC), ne...